Brainsway Ltd. has announced a significant expansion of its insurance coverage for Deep Transcranial Magnetic Stimulation (Deep TMS) treatment for obsessive-compulsive disorder (OCD). This expansion now covers over 118 million lives across the United States, marking a critical milestone in the company's efforts to enhance patient access to innovative mental health therapies.

The announcement was made on October 26, 2026, and highlights Brainsway's commitment to broadening access to evidence-based treatments for mental health disorders. Hadar Levy, the Chief Executive Officer of Brainsway, stated, "Reaching more than 118 million covered lives represents meaningful progress in expanding access to Deep TMS for patients living with this challenging condition." This expansion is seen as a vital step in the company's ongoing strategy to work with insurers and healthcare providers to increase coverage and reduce barriers to treatment.

Background

Brainsway Ltd. is a global leader in advanced noninvasive brain stimulation technologies, primarily focusing on mental health disorders. The company operates under the SIC classification of 3841, which pertains to Surgical & Medical Instruments & Apparatus. Brainsway is publicly traded on Nasdaq under the ticker BWAY and also on the OTC market as BRSYF. Recent filings include a 6-K on October 26, 2026, and further amendments to this filing.

What the Filing Says

The filing states, "With this latest expansion, more than 118 million Americans are now covered under insurance policies that provide access to BrainsWay Deep TMS for OCD." This statement underscores the company's strategic focus on increasing insurance coverage for its innovative treatment options.

Impact

This expansion in insurance coverage may significantly affect patients suffering from OCD, providing them with better access to treatment options that were previously limited. Additionally, it positions Brainsway favorably against competitors in the surgical and medical instruments sector, as it enhances their market presence and credibility in the mental health treatment landscape.

What's Next

The filing does not say what happens next.